Precision Medicine

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

Amid rising drug price scrutiny, Red Nucleus acquires an AI-powered consultancy to revolutionize how biopharma proves the value of new medicines.

As AI systems deny healthcare claims at alarming rates, experts argue that human oversight is the only safeguard for both patients and payors.

Praxis and SEQSTER expand their alliance, leveraging a powerful data platform to speed up development of new treatments for epilepsy and other CNS disorders.

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

At MD&M West 2026, Boyd showcases how materials science and regulatory expertise are the unsung heroes behind the next wave of medical wearables.

Mwyngil Therapeutics starts clinical trials for a novel brain-penetrating drug, aiming to tackle neuroinflammation at its source in MS and Parkinson's.

A new FAIR Health report finds 57.5% of commercially insured Americans have a chronic condition, with costs nearly doubling for patients with just one.

Early clinical results for MP0712, a novel Radio-DARPin, suggest a breakthrough for targeting aggressive cancers like SCLC while sparing healthy tissue.

After Amgen steps back, Kyowa Kirin takes full control of its promising atopic dermatitis drug, rocatinlimab, betting on its unique science.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

A new global survey reveals millions of women are unprepared for menopause's skin impact. One company is now pushing for a new standard in research.

A Bolingbrook senior care provider earns a prestigious certification, adopting an evidence-based framework that promises a new level of personalized care.

With a key nod from NCCN guidelines and strong clinical data, high-resolution micro-ultrasound is now a powerful, accessible alternative to MRI.

The FDA has qualified MolecuLightDX's measurement tool, a move set to standardize clinical trials, accelerate innovation, and redefine wound healing.

The new SecureFlex™ device aims to improve tissue sampling for diseases like pancreatic cancer, enabling more precise diagnoses and personalized treatments.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

A new study in Nature Medicine shows a fasting-mimicking diet led to high remission rates in Crohn's patients, heralding a new era for 'Food as Medicine'.

Stoke Therapeutics' major new lease in Waltham signals a pivotal shift to commercialization and defies a cooling life sciences real estate market.